JIU-JITSU WITH MISINFORMATION IN THE AGE OF COVID: USING REFUTATION-BASED LEARNING TO ENHANCE VACCINE UPTAKE AND KNOWLEDGE AMONG HEALTHCARE PROFESSIONALS AND THE PUBLIC
Acronym
JITSUVAX
Description of the granted funding
Vaccine hesitancy—the delay or refusal of vaccination without medical indication—has been cited as a serious threat to global health by the World Health Organization (WHO), attributing it to misinformation on the internet. The WHO has also identified Health Care Professionals (HCPs) as the most trusted influencers of vaccination decisions.
JITSUVAX leverages those insights to turn toxic misinformation into a potential asset based on two premises: 1. The best way to acquire knowledge and to combat misperceptions is by employing misinformation itself, either in weakened doses as a cognitive “vaccine”, or through thorough analysis of misinformation during “refutational learning”. 2. HCPs form the critical link between vaccination policies and vaccine uptake.
The principal objective of JITSUVAX is to leverage misinformation about vaccinations into an opportunity by training HCPs through inoculation and refutational learning, thereby neutralizing misinformation among HCPs and enabling them to communicate more effectively with patients. JITSUVAX comprises 4 scientific work packages (WPs 1-4), plus one Management WP (WP0).
WP1 will systematically measure HCP attitudes towards vaccinations across participating countries.
WP2 will analyse argumentation by anti-vaccination activists to provide material for inoculation and refutational learning. WP2 will also develop novel tools that improve public resilience to misinformation and HCP’s knowledge and attitudes concerning vaccinations.
WP3 will translate the findings from WP1 and WP2 into practice, by exploring several new tools, ranging from a new “empathic refutational interview” to interventions in the training of HCPs.
WP4 focuses on impact and dissemination. WP4 will design and develop a guidance document for HCPs and public health bodies. Through the team’s contacts and previous collaborations with WHO and UNICEF, we will disseminate and leverage our new knowledge for global impact.
Show moreStarting year
2021
End year
2025
Granted funding
UNIVERSIDADE DE COIMBRA (PT)
238 123.75 €
Participant
OBSERVATOIRE REGIONAL DE LA SANTE (FR)
404 413.75 €
Participant
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE (UK)
235 770 €
Participant
NCC OPERATIONS LIMITED (UK)
1 134 894.74 €
Coordinator
UNIVERSITAT ERFURT (DE)
666 521.75 €
Participant
Amount granted
3 118 833 €
Funder
European Union
Funding instrument
Research and Innovation action
Framework programme
Horizon 2020 Framework Programme
Call
Programme part
Health (5290 Preventing disease (5295 )
Topic
Addressing low vaccine uptake (SC1-BHC-33-2020Call ID
H2020-SC1-2020-Single-Stage-RTD Other information
Funding decision number
964728
Identified topics
covid, pandemic, vaccines